Orlistat for the Treatment of Type I Hyperlipoproteinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

December 31, 2022

Conditions
Hyperlipoproteinemia Type IHypertriglyceridemia
Interventions
DRUG

Orlistat

Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.

Trial Locations (1)

75390-8537

UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02767531 - Orlistat for the Treatment of Type I Hyperlipoproteinemia | Biotech Hunter | Biotech Hunter